Recombinant CD33 (Gemtuzumab Biosimilar) antibody

Catalog No. ABIN7795111

This anti-CD33 (Gemtuzumab Biosimilar) antibody is a Humanized Monoclonal antibody detecting CD33 (Gemtuzumab Biosimilar) in FACS and in vivo. Suitable for Human.

Quick Overview for Recombinant CD33 (Gemtuzumab Biosimilar) antibody (ABIN7795111)

Target: CD33 (Gemtuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This CD33 (Gemtuzumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CD33 (Gemtuzumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Gemtuzumab Biosimilar, CD33 Monoclonal Antibody

Characteristics: Gemtuzumab is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50 % of the antibody loaded with 4-6 Moles calicheamicin per mole of antibody Label. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. Gemtuzumab is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Gemtuzumab with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in site-specific DNA double strand breaks via formation of a p-benzene diradical. Eventually, cell death is induced.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CD33

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CD33 (Gemtuzumab Biosimilar)

Target: CD33 (Gemtuzumab Biosimilar)

Alternative Name: Gemtuzumab Biosimilar

Target Type: Biosimilar